Pemetrexed (Alimta) was approved by the FDA in 2004 and remains the just drug specifically approved for the treatment of mesothelioma, a virulent cancer carefully linked to asbestos exposure.
Although pemetrexed is the a lot of common drug treatment for mesothelioma, it is much from universally effective. In fact, just concerning 4 from 10 mesothelioma patients will incentive from treatment along with pemetrexed.
Boosting Mesothelioma Chemotherapy
One need pemetrexed has actually such difficulty killing mesothelioma cells is that many cell lines of the cancer are resistant to its damaging effects. Overexpression of a certain enzyme called thymidylate synthase (TS) has actually been linked to this resistance.
This week, a brand-new study conducted at Italy’s University of Torino finds that a drug usually used to treat leukemia has the potential to extend mesothelioma survival by improving the cancer-killing electricity of pemetrexed.
The drug, called dasatinib (Sprycel), is a targeted therapy that inhibits certain tyrosine kinases, enzymes that play a important role in the growth and proliferation of cancer cells. Developed by Bristol-Myers Squibb, dasatinib is approved for initial line treatment of people along with chronic myelogenous leukemia and acute lymphoblastic leukemia.
Testing Dasatinib as a Mesothelioma Treatment
To find out whether dasatinib can be a practical addition to mesothelioma chemotherapy treatment, University of Torino researchers exposed 3 different mesothelioma cell lines to pemetrexed alone, dasatinib alone, one ideal after the other, or a combination of both drugs.
After every treatment approach, the researchers tested the viability of the mesothelioma cells, the fee of apoptosis (cell death) and migration, TS expression and others parameters.
“Dasatinib treatment impaired cells migration, and the two sequential and co-administration along with PEM [pemetrexed] significantly increased apoptosis,” reports study study author Dr. Valentina Monica, an oncologist along with San Luigi Hospital at the University of Torino. ”These data indicate that dasatinib sensitizes mesothelioma cells to pemetrexed through TS downregulation.”
If the outcomes of this targeted mesothelioma therapy approach can easily be confirmed in subsequent studies, it can be great news for the 2,500 Americans diagnosed along with the asbestos cancer every year. Also along with the a lot of advanced mesothelioma therapies currently known, including pemetrexed-based chemotherapy, the odds of long term mesothelioma survival remain low.
Source:
Monica, V, et al, “Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines”, July 6, 2016, Oncotarget, Epub ahead of print
Summary
Article Name
Mesothelioma Chemotherapy might grab an improvement from Leukemia Drug
Description
There is brand-new evidence that a drug made to manage leukemia might insight improve the efficiency of the a lot of popular chemotherapy drug for malignant mesothelioma.
Author
Alex Strauss
